Amylyx Pharmaceuticals, Inc. Share Price: AMLX (Amylyx Pharmaceuticals, Inc.) Stock Price Today & Updates | INDmoney

Question 1

What is Amylyx Pharmaceuticals, Inc. share price today?

Accepted Answer

Amylyx Pharmaceuticals, Inc. (AMLX) share price today is {{live_price}}.

Question 2

Can Indians buy Amylyx Pharmaceuticals, Inc. shares?

Accepted Answer

Yes, Indians can invest in the Amylyx Pharmaceuticals, Inc. (AMLX) from India.

With INDmoney, you can buy Amylyx Pharmaceuticals, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amylyx Pharmaceuticals, Inc. at zero transaction cost.

Question 3

How can I buy Amylyx Pharmaceuticals, Inc. shares from India?

Accepted Answer

It is very easy to buy Amylyx Pharmaceuticals, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Amylyx Pharmaceuticals, Inc. be purchased?

Accepted Answer

Yes, you can buy fractional shares of Amylyx Pharmaceuticals, Inc. with INDmoney app.

Question 5

What are the documents required to start investing in Amylyx Pharmaceuticals, Inc. stocks?

Accepted Answer

To start investing in Amylyx Pharmaceuticals, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Amylyx Pharmaceuticals, Inc.

Accepted Answer

Today’s highest price of Amylyx Pharmaceuticals, Inc. (AMLX) is {{1_rba_end}}.

Today’s lowest price of Amylyx Pharmaceuticals, Inc. (AMLX) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Amylyx Pharmaceuticals, Inc.

Accepted Answer

Today's market capitalisation of Amylyx Pharmaceuticals, Inc. AMLX is 266.9M

Question 8

What is the 52 Week High and Low Range of Amylyx Pharmaceuticals, Inc.

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Amylyx Pharmaceuticals, Inc. is down from its 52 Week High?

Accepted Answer

Amylyx Pharmaceuticals, Inc. (AMLX) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Amylyx Pharmaceuticals, Inc. is up from its 52 Week low?

Accepted Answer

Amylyx Pharmaceuticals, Inc. (AMLX) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Amylyx Pharmaceuticals, Inc.?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Amylyx Pharmaceuticals, Inc.

Accepted Answer

Mr. Joshua B. Cohen is the current Chief Executive Officer (CEO) of Amylyx Pharmaceuticals, Inc..

Period	Amylyx Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	141.41%	3.6%	0.0%
6 Months	141.41%	10.2%	0.0%
1 Year	-70.94%	19.6%	0.0%
3 Years	-73.55%	16.8%	-23.0%

Market Capitalization	266.9M
Book Value	$3.84
Earnings Per Share (EPS)	-2.46
Wall Street Target Price	4.25

Profit Margin	-55.52%
Operating Margin TTM	7457.09%

Return On Assets TTM	-28.28%
Return On Equity TTM	-51.22%

Revenue TTM	298.8M
Revenue Per Share TTM	4.41
Quarterly Revenue Growth YOY	24.099999999999998%
Gross Profit TTM	-74.2M
EBITDA	-176.6M
Diluted Eps TTM	-2.46
Quarterly Earnings Growth YOY	0.0

Amylyx Pharmaceuticals, Inc. (AMLX)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Decreasing Revenue

Increasing Net Profit

Vs ALNY

Institutional Holdings

Company Information

Discover More

FAQs

EPS Estimate Current Year	-4.13
EPS Estimate Next Year	-1.91
EPS Estimate Current Quarter	-0.73
EPS Estimate Next Quarter	-0.64

	FY20	Y/Y Change
Revenue	650.0K	↓ 54.42%
Net Income	-44.8M	↑ 202.63%
Net Profit Margin	-6.9K%	↓ 5859.01%

	FY21	Y/Y Change
Revenue	285.0K	↓ 56.15%
Net Income	-87.9M	↑ 96.0%
Net Profit Margin	-30.8K%	↓ 23936.74%

	FY22	Y/Y Change
Revenue	22.2M	↑ 7700.0%
Net Income	-198.4M	↑ 125.74%
Net Profit Margin	-892.38%	↑ 29942.36%

	FY23	Y/Y Change
Revenue	380.8M	↑ 1612.94%
Net Income	49.3M	↓ 124.84%
Net Profit Margin	12.94%	↑ 905.32%

	Q1 FY23	Q/Q Change
Revenue	71.4M	↑ 226.38%
Net Income	1.6M	↓ 103.68%
Net Profit Margin	2.2%	↑ 197.33%

	Q2 FY23	Q/Q Change
Revenue	98.2M	↑ 37.5%
Net Income	22.1M	↑ 1303.31%
Net Profit Margin	22.47%	↑ 20.27%

	Q3 FY23	Q/Q Change
Revenue	102.7M	↑ 4.56%
Net Income	20.9M	↓ 5.35%
Net Profit Margin	20.35%	↓ 2.12%

	Q4 FY23	Q/Q Change
Revenue	108.4M	↑ 5.61%
Net Income	4.7M	↓ 77.36%
Net Profit Margin	4.36%	↓ 15.99%

	Q1 FY24	Q/Q Change
Revenue	88.6M	↓ 18.26%
Net Income	-118.8M	↓ 2610.95%
Net Profit Margin	-134.01%	↓ 138.37%

	FY19	Y/Y Change
Total Assets	3.2M	-
Total Liabilities	28.6M	-

	FY20	Y/Y Change
Total Assets	14.1M	↑ 338.01%
Total Liabilities	80.8M	↑ 182.85%

	FY21	Y/Y Change
Total Assets	105.6M	↑ 648.82%
Total Liabilities	256.8M	↑ 217.69%

	FY22	Y/Y Change
Total Assets	391.5M	↑ 270.64%
Total Liabilities	50.8M	↓ 80.2%

	Q2 FY24	Q/Q Change
Revenue	-1.0M	↓ 101.15%
Net Income	-72.7M	↓ 38.8%
Net Profit Margin	7.1K%	↑ 7240.57%

	FY23	Y/Y Change
Total Assets	517.5M	↑ 32.19%
Total Liabilities	84.0M	↑ 65.25%

	Q2 FY23	Q/Q Change
Total Assets	453.6M	↑ 11.18%
Total Liabilities	67.2M	↑ 21.54%

	Q1 FY24	Q/Q Change
Total Assets	417.5M	↓ 19.32%
Total Liabilities	93.0M	↑ 10.71%

	Q2 FY24	Q/Q Change
Total Assets	332.2M	↓ 20.43%
Total Liabilities	70.9M	↓ 23.83%

	FY19	Y/Y Change
Operating Cash Flow	-10.7M	-
Investing Cash Flow	-151.0K	-
Financing Cash Flow	668.0K	-

	FY20	Y/Y Change
Operating Cash Flow	-36.7M	↑ 243.38%
Investing Cash Flow	-151.0K	↑ 0.0%
Financing Cash Flow	46.8M	↑ 6909.43%

	FY21	Y/Y Change
Operating Cash Flow	-74.8M	↑ 103.83%
Investing Cash Flow	-46.4M	↑ 30632.45%
Financing Cash Flow	158.5M	↑ 238.52%

	FY22	Y/Y Change
Operating Cash Flow	-179.9M	↑ 140.47%
Investing Cash Flow	-239.0M	↑ 414.99%
Financing Cash Flow	431.8M	↑ 172.41%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-5.1M	↓ 89.79%
Investing Cash Flow	56.0M	↓ 124.54%
Financing Cash Flow	1.0M	↓ 99.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	8.6M	↓ 269.74%
Investing Cash Flow	123.2M	↑ 120.06%
Financing Cash Flow	1.4M	↑ 33.08%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amylyx Pharmaceuticals, Inc.	64.26%	141.41%	-70.94%	-73.55%	-73.55%
Regeneron Pharmaceuticals, Inc.	-9.28%	10.06%	24.53%	74.0%	232.45%
Novo Nordisk A/s	-4.54%	-5.72%	21.59%	126.2%	349.01%
Alnylam Pharmaceuticals, Inc.	8.87%	102.98%	82.67%	44.83%	241.09%
Vertex Pharmaceuticals Incorporated	5.0%	20.77%	31.37%	158.16%	163.17%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amylyx Pharmaceuticals, Inc.	2.51	NA	NA	-4.13	-0.51	-0.28	NA	3.84
Regeneron Pharmaceuticals, Inc.	26.41	26.41	1.37	44.9	0.17	0.08	NA	261.41
Novo Nordisk A/s	40.21	40.21	1.81	3.36	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.42	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.59	0.18	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amylyx Pharmaceuticals, Inc.	Buy	$266.9M	-73.55%	2.51	-55.52%
Regeneron Pharmaceuticals, Inc.	Buy	$110.0B	232.45%	26.41	32.04%
Novo Nordisk A/s	Buy	$529.8B	349.01%	40.21	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$38.1B	241.09%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$128.7B	163.17%	32.84	-4.74%

Organization	Amylyx Pharmaceuticals, Inc.
Employees	384
CEO	Mr. Joshua B. Cohen
Industry	Services